What is Viking Therapeutics, Inc's earnings per share (EPS)?

Viking Therapeutics, Inc (VKTX) reported diluted earnings per share of -$3.19 for fiscal year 2025. This represents a -215.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Viking Therapeutics, Inc (VKTX) Financials

VKTX

FY2025 annual

Revenue $0 YoY not available

Net Income -$359.6M -227.1% YoY

EPS (Diluted) -$3.19 -215.8% YoY

Operating Cash Flow -$278.7M -217.4% YoY

Market Cap $3.6B as of Oct 13, 2026

Price / Sales n/m revenue is not positive, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 8.8x on $408.3M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Jul 29, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Jul 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VKTX SEC filings page.

Viking Therapeutics, Inc (VKTX) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI VKTX FY2025 2026-10-04

Viking remains a research-funded business: FY2025 investment accelerated while operations consumed cash and external financing remained important.

FY2025 R&D reached $345M while operating cash flow was -$278.7M, linking the cash requirement primarily to an expanding research program rather than administrative spending alone. The net loss was $359.6M, close to that cash outflow, so accounting losses and cash consumption broadly agree.

The balance sheet is still predominantly equity-funded: FY2025 liabilities were $76.7M against $715.7M of assets, while debt-to-equity was 0.1x. A 9.3x current ratio and 30.4 months of reported outflow comparison indicate considerable short-term financial capacity relative to reported obligations.

Financing supplied $612.5M in FY2024 but only $76.4M in FY2025, while operating cash outflow widened from $87.8M to $278.7M. This means the cash position has been shaped by financing and investment flows, not operating receipts.

Financial Health Signals

Financial health score not available

Viking Therapeutics, Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Safe

25.80

Viking Therapeutics, Inc scores 25.80, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($3.6B) relative to total liabilities ($76.7M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

1/7

Viking Therapeutics, Inc passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Viking Therapeutics, Inc reported a net loss of $359.6M while operations used $278.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

Viking Therapeutics, Inc generated $0 in revenue in Q2 2026.

Net Income

-$128.0M

YoY-95.3%

QoQ+19.1%

Viking Therapeutics, Inc reported -$128.0M in net income in Q2 2026. This represents a decrease of 95.3% from the same quarter a year earlier. Against the prior quarter it is up 19.1%.

EPS (Diluted)

-$1.10

YoY-89.7%

QoQ+19.7%

Viking Therapeutics, Inc earned -$1.10 per diluted share (EPS) in Q2 2026. This represents a decrease of 89.7% from the same quarter a year earlier. Against the prior quarter it is up 19.7%.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$125.8M

YoY+271.2%

QoQ+6.5%

5Y CAGR+70.1%

10Y CAGR+37.6%

Viking Therapeutics, Inc held $125.8M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

117M

YoY+3.7%

QoQ+0.5%

5Y CAGR+8.3%

10Y CAGR+19.7%

Viking Therapeutics, Inc had 117M shares outstanding in Q2 2026. This represents an increase of 3.7% from the same quarter a year earlier. Against the prior quarter it is up 0.5%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-31.4%

YoY-23.1pp

QoQ+0.2pp

Viking Therapeutics, Inc's ROE was -31.4% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 23.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.2 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$115.8M

YoY+92.4%

QoQ-22.9%

Viking Therapeutics, Inc invested $115.8M in research and development in Q2 2026. This represents an increase of 92.4% from the same quarter a year earlier. Against the prior quarter it is down 22.9%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

VKTX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VKTX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Revenue	N/A	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
R&D Expenses	N/A	$345.0M+239.4%	$101.6M+59.3%	$63.8M+17.6%	$54.2M+20.6%	$45.0M+40.9%	$31.9M+35.5%	$23.6M+23.7%	$19.0M+38.6%	$13.7M+52.7%	$9.0M+29.2%	$7.0M	N/A
SG&A Expenses	N/A	$48.4M-1.8%	$49.3M+33.1%	$37.0M+129.6%	$16.1M+50.6%	$10.7M-0.3%	$10.7M+17.6%	$9.1M+28.2%	$7.1M+33.6%	$5.3M+9.9%	$4.8M-3.6%	$5.0M+304.0%	$1.2M
Operating Income	N/A	-$393.3M-160.6%	-$150.9M-49.7%	-$100.8M-43.3%	-$70.4M-26.4%	-$55.7M-30.5%	-$42.7M-30.5%	-$32.7M-24.9%	-$26.2M-37.2%	-$19.1M-37.7%	-$13.8M-15.4%	-$12.0M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$22K-75.3%	$89K+25.4%	$71K
Income Tax	N/A	$1K0.0%	$1K0.0%	$1K0.0%	$1K-50.0%	$2K	$0	$0	$0	$0	$0	N/A	N/A
Net Income	N/A	-$359.6M-227.1%	-$110.0M-28.0%	-$85.9M-24.7%	-$68.9M-25.2%	-$55.0M-39.2%	-$39.5M-53.2%	-$25.8M-16.8%	-$22.1M-7.2%	-$20.6M-39.7%	-$14.7M+37.1%	-$23.4M	N/A
EPS (Basic)	N/A	-$3.19-215.8%	-$1.01-11.0%	-$0.91-1.1%	-$0.90-26.8%	-$0.71	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$4.67	-$3.19-215.8%	-$1.01-11.0%	-$0.91-1.1%	-$0.90-26.8%	-$0.71	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	113M+3.3%	109M+15.6%	94M+22.8%	77M-0.5%	77M	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$0	$0	N/A	$0	$0	$0	N/A	$0
R&D Expenses	$115.8M+92.4%	$150.2M+262.8%	N/A	$90.0M+294.8%	$60.2M+153.1%	$41.4M+71.7%	N/A	$22.8M+24.0%
SG&A Expenses	$16.8M+16.8%	$14.0M-0.7%	N/A	$8.6M-37.5%	$14.4M+40.2%	$14.1M+41.2%	N/A	$13.8M+55.0%
Operating Income	-$132.6M-77.8%	-$164.1M-195.9%	N/A	-$98.6M-169.6%	-$74.6M-119.0%	-$55.5M-62.8%	N/A	-$36.6M-34.1%
Net Income	-$128.0M-95.3%	-$158.3M-247.0%	N/A	-$90.8M-264.0%	-$65.6M-194.7%	-$45.6M-66.8%	N/A	-$24.9M-10.7%
EPS (Basic)	-$1.10-89.7%	-$1.37-234.1%	-$1.39-334.4%	-$0.81-268.2%	-$0.58-190.0%	-$0.41-57.7%	-$0.32-28.0%	-$0.22+4.3%
EPS (Diluted)	-$1.10-89.7%	-$1.37-234.1%	-$1.39-334.4%	-$0.81-268.2%	-$0.58-190.0%	-$0.41-57.7%	-$0.32-28.0%	-$0.22+4.3%
Diluted Shares (Avg)	116M+3.7%	116M+3.1%	N/A	112M+1.3%	112M+1.6%	112M+8.3%	N/A	111M+11.1%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EBITDA, Interest Expense, Income Tax.

VKTX Balance Sheet

VKTX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Total Assets	$715.7M-21.2%	$908.3M+146.5%	$368.5M+118.7%	$168.5M-20.0%	$210.7M-17.9%	$256.5M-9.8%	$284.3M-6.0%	$302.3M+1266.6%	$22.1M+52.2%	$14.5M-5.9%	$15.4M+407.3%	$3.0M
Current Assets	$715.6M-21.1%	$907.2M+147.0%	$367.2M+119.8%	$167.0M-20.7%	$210.5M-17.8%	$256.1M-9.7%	$283.5M-6.2%	$302.1M+1282.7%	$21.9M+56.4%	$14.0M-8.1%	$15.2M+1864.8%	$774K
Cash & Equivalents	$165.8M+521.6%	$26.7M-51.9%	$55.5M+51.6%	$36.6M+38.9%	$26.4M-9.4%	$29.1M+247.6%	$8.4M-66.2%	$24.8M+175.7%	$9.0M+192.2%	$3.1M+300.2%	$769K+1.7%	$756K
Short-Term Investments	$539.9M-38.4%	$875.9M+185.7%	$306.6M+157.9%	$118.9M-32.4%	$175.7M-19.9%	$219.3M-18.0%	$267.3M-3.4%	$276.7M+2288.4%	$11.6M+15.0%	$10.1M-24.4%	$13.3M	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$76.7M+173.4%	$28.0M+39.7%	$20.1M-13.5%	$23.2M+164.4%	$8.8M-27.8%	$12.2M+70.4%	$7.1M+56.4%	$4.6M-47.3%	$8.7M+33.3%	$6.5M-3.3%	$6.7M-73.3%	$25.2M
Current Liabilities	$76.7M+179.7%	$27.4M+43.3%	$19.1M-12.8%	$21.9M+150.0%	$8.8M-27.6%	$12.1M+79.0%	$6.8M+48.9%	$4.5M-47.4%	$8.7M+33.7%	$6.5M+227.6%	$2.0M-91.2%	$22.5M
Non-Current Liabilities	$0-100.0%	$630K-32.7%	$936K-25.7%	$1.3M	$0-100.0%	$29K-91.9%	$360K+2900.0%	$12K	$0-100.0%	$16K-99.7%	$4.7M+78.5%	$2.7M
Total Equity	$639.1M-27.4%	$880.3M+152.6%	$348.4M+139.8%	$145.3M-28.0%	$201.9M-17.4%	$244.3M-11.8%	$277.1M-6.9%	$297.8M+2111.5%	$13.5M+67.4%	$8.0M-7.8%	$8.7M+139.4%	-$22.1M
Retained Earnings	-$847.5M-73.7%	-$487.9M-29.1%	-$377.9M-29.4%	-$292.0M-30.9%	-$223.2M-32.7%	-$168.2M-30.7%	-$128.7M-25.0%	-$102.9M-27.3%	-$80.9M-34.1%	-$60.3M-32.3%	-$45.5M-105.7%	-$22.1M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$521.9M-37.0%	$608.2M-29.8%	$715.7M-21.2%	$739.4M-21.2%	$827.9M-12.6%	$867.0M-10.4%	$908.3M+146.5%	$937.9M+145.1%
Current Assets	$517.6M-37.4%	$608.2M-29.8%	$715.6M-21.1%	$738.7M-21.1%	$827.0M-12.6%	$866.0M-10.4%	$907.2M+147.0%	$936.6M+145.6%
Cash & Equivalents	$125.8M+271.2%	$118.1M+211.3%	$165.8M+521.6%	$100.4M+99.4%	$33.9M-22.9%	$37.9M-80.6%	$26.7M-51.9%	$50.3M+35.4%
Short-Term Investments	$375.9M-51.4%	$484.8M-40.4%	$539.9M-38.4%	$614.2M-30.2%	$773.8M-13.9%	$813.9M+6.1%	$875.9M+185.7%	$880.1M+159.6%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$113.6M+250.7%	$106.3M+429.6%	$76.7M+173.4%	$26.4M-0.2%	$32.4M+25.3%	$20.1M-40.3%	$28.0M+39.7%	$26.4M+83.3%
Current Liabilities	$109.7M+242.9%	$106.3M+443.2%	$76.7M+179.7%	$26.1M+1.5%	$32.0M+27.4%	$19.6M-40.3%	$27.4M+43.3%	$25.7M+91.6%
Non-Current Liabilities	$3.9M+857.3%	$0-100.0%	$0-100.0%	$318K-57.9%	$410K-46.5%	$502K-41.1%	$630K-32.7%	$755K-25.8%
Total Equity	$408.3M-48.7%	$501.9M-40.7%	$639.1M-27.4%	$713.0M-21.8%	$795.5M-13.6%	$846.9M-9.3%	$880.3M+152.6%	$911.4M+147.5%
Retained Earnings	-$1.1B-89.3%	-$1.0B-88.5%	-$847.5M-73.7%	-$689.9M-52.5%	-$599.1M-40.1%	-$533.5M-31.6%	-$487.9M-29.1%	-$452.5M-28.1%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

VKTX Cash Flow Statement

VKTX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Operating Cash Flow	-$418.4M	-$278.7M-217.4%	-$87.8M-19.6%	-$73.4M-51.6%	-$48.4M-1.7%	-$47.6M-118.5%	-$21.8M+12.0%	-$24.8M-32.0%	-$18.8M-27.1%	-$14.8M-33.3%	-$11.1M-26.8%	-$8.7M-448.7%	-$1.6M
Stock-Based Compensation	N/A	$40.8M+37.4%	$29.7M+77.4%	$16.8M+93.1%	$8.7M+42.2%	$6.1M+4.8%	$5.8M+55.4%	$3.7M+43.5%	$2.6M+79.7%	$1.5M-19.1%	$1.8M-31.0%	$2.6M+41470.0%	$6K
Investing Cash Flow	$399.3M	$341.4M+161.7%	-$553.4M-209.0%	-$179.1M-427.1%	$54.8M+44.2%	$38.0M-8.7%	$41.6M+457.0%	$7.5M+102.8%	-$265.7M-15260.1%	-$1.7M	N/A	N/A	N/A
Financing Cash Flow	$111.2M	$76.4M-87.5%	$612.5M+125.7%	$271.4M+6418.8%	$4.2M-39.5%	$6.9M+624.2%	$950K+7.1%	$887K-99.7%	$300.3M+1240.5%	$22.4M	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	$6.8M	N/A	N/A	N/A	N/A	N/A	$229+502.6%	$38+1800.0%	$2

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$125.2M-166.0%	-$114.0M-117.8%	-$85.3M-173.5%	-$94.0M-328.0%	-$47.1M-65.1%	-$52.3M-753.1%	-$31.2M-76.8%	-$22.0M-11.7%
Stock-Based Compensation	$11.1M-17.8%	$10.3M-8.9%	N/A	$7.3M-18.3%	$13.5M+91.3%	$11.3M+42.2%	N/A	$9.0M+100.4%
Investing Cash Flow	$109.4M+157.4%	$54.2M-14.3%	$75.6M+1048.4%	$160.0M+517.8%	$42.5M+133.7%	$63.2M+113.8%	$6.6M-81.6%	$25.9M+306.6%
Financing Cash Flow	$23.6M+4552.1%	$12.1M+3360.5%	$75.1M+7410.3%	$480K-81.0%	$507K-82.5%	$349K-99.9%	$1.0M+431.9%	$2.5M+3508.1%

Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

VKTX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VKTX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Return on Equity	-56.3%-43.8pp	-12.5%+12.2pp	-24.6%+22.7pp	-47.4%-20.2pp	-27.2%-11.1pp	-16.2%-6.9pp	-9.3%-1.9pp	-7.4%+145.4pp	-152.8%+30.3pp	-183.2%+85.1pp	-268.2%	N/A
Return on Assets	-50.2%-38.1pp	-12.1%+11.2pp	-23.3%+17.6pp	-40.9%-14.8pp	-26.1%-10.7pp	-15.4%-6.3pp	-9.1%-1.8pp	-7.3%+85.7pp	-93.0%+8.3pp	-101.4%+50.2pp	-151.6%	N/A
Current Ratio	9.33-23.8x	33.09+13.9x	19.19+11.6x	7.61-16.4x	23.98+2.9x	21.11-20.7x	41.83-24.6x	66.40+63.9x	2.52+0.4x	2.16-5.5x	7.69+7.7x	0.03
Debt-to-Equity	0.12+0.1x	0.030.0x	0.06-0.1x	0.16+0.1x	0.040.0x	0.050.0x	0.030.0x	0.02-0.6x	0.64-0.2x	0.810.0x	0.77	N/A
Asset Turnover	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.00

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-31.4%-23.1pp	-31.5%-26.2pp	N/A	-12.7%-10.0pp	-8.2%-5.8pp	-5.4%-2.5pp	N/A	-2.7%+3.4pp
Return on Assets	-24.5%-16.6pp	-26.0%-20.8pp	N/A	-12.3%-9.6pp	-7.9%-5.6pp	-5.3%-2.4pp	N/A	-2.7%+3.2pp
Current Ratio	4.72-21.1x	5.72-38.5x	9.33-23.8x	28.34-8.1x	25.86-11.8x	44.25+14.8x	33.09+13.9x	36.47+8.0x
Debt-to-Equity	0.28+0.2x	0.21+0.2x	0.12+0.1x	0.040.0x	0.040.0x	0.020.0x	0.030.0x	0.030.0x
Asset Turnover	0.000.0x	0.000.0x	N/A	0.000.0x	0.000.0x	0.000.0x	N/A	0.000.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Viking Therapeutics, Inc VKTX	FY2025	$0	-$359.6M	N/A	$3.6B	—
Immunovant, Inc. IMVT	FY2026	N/A	-$505.6M	N/A	$6.1B	—
Xenon Pharmaceuticals Inc XENE	FY2025	$7.5M	-$345.9M	N/A	$3.5B	54/100
Crinetics Pharmaceuticals, Inc. CRNX	FY2025	$7.7M	-$465.3M	N/A	$9.0B	60/100
Scholar Rock Holding Corporation SRRK	FY2025	$0	-$378.0M	N/A	$5.1B	—
Soleno Therapeutics, Inc. SLNO	FY2025	$190.4M	$20.9M	11.0%	$2.8B	59/100

Where Viking Therapeutics, Inc Ranks

Frequently Asked Questions

What is Viking Therapeutics, Inc's annual revenue?

Viking Therapeutics, Inc (VKTX) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Viking Therapeutics, Inc profitable?

No, Viking Therapeutics, Inc (VKTX) reported a net income of -$359.6M in fiscal year 2025.

What is Viking Therapeutics, Inc's return on equity (ROE)?

Viking Therapeutics, Inc (VKTX) has a return on equity of -56.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Viking Therapeutics, Inc's operating cash flow?

Viking Therapeutics, Inc (VKTX) recorded an outflow of $278.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Viking Therapeutics, Inc's total assets?

Viking Therapeutics, Inc (VKTX) had $715.7M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Viking Therapeutics, Inc spend on research and development?

Viking Therapeutics, Inc (VKTX) invested $345.0M in research and development during fiscal year 2025.

How many shares does Viking Therapeutics, Inc have outstanding?

Viking Therapeutics, Inc (VKTX) had 116M shares outstanding as of fiscal year 2025.

What is Viking Therapeutics, Inc's current ratio?

Viking Therapeutics, Inc (VKTX) had a current ratio of 9.33 as of fiscal year 2025, which is generally considered healthy.

What is Viking Therapeutics, Inc's debt-to-equity ratio?

Viking Therapeutics, Inc (VKTX) had a debt-to-equity ratio of 0.12 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Viking Therapeutics, Inc's return on assets (ROA)?

Viking Therapeutics, Inc (VKTX) had a return on assets of -50.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Viking Therapeutics, Inc's P/E ratio?

Viking Therapeutics, Inc (VKTX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $3.6B as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Viking Therapeutics, Inc's price-to-sales ratio?

Viking Therapeutics, Inc (VKTX) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $3.6B as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Viking Therapeutics, Inc's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Viking Therapeutics, Inc (VKTX) held $705.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $278.7M over that year. Dividing the one by the other, the reported balance equals about 30 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Viking Therapeutics, Inc's Altman Z-Score?

Viking Therapeutics, Inc (VKTX) has an Altman Z-Score of 25.80, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Viking Therapeutics, Inc's Piotroski F-Score?

Viking Therapeutics, Inc (VKTX) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Viking Therapeutics, Inc's earnings high quality?

Viking Therapeutics, Inc (VKTX) reported a net loss of $359.6M while operations used $278.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.